The FDA has designated the filing as a complete, Class 1 response with a PDUFA target action date of August 2, 2026. The Food and Drug Administration (FDA) has accepted for review Replimune’s ...
Trodelvy is now FDA-approved for first-line treatment of advanced TNBC, significantly improving PFS in phase 3 trials.
The phase 3b trial evaluated 315 adults specifically dealing with ADHD alongside comorbid generalized anxiety disorder and/or social anxiety disorder.
Tryngolza (olezarsen) is the first approved therapy to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia.
Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.
The novel topical gel, designed to clear mutant keratin aggregates and restore intermediate filament network integrity via autophagy, is undergoing evaluation in the phase 2 TAMES-02 trial.
The FDA wants to remove a limitation stating that the therapy's safety and effectiveness have not been established in men with age-related low testosterone ...
Saliency-based score highlighted biologically meaningful regions, especially the optic nerve head and retinal vasculature.
Rifapentine is a cyclopentyl rifamycin antimycobacterial agent indicated for the treatment of active pulmonary tuberculosis and late tuberculosis infection.
In patients with 1 prior line of systemic therapy, the IB6-directed ADC showed favorable trends in both overall survival and progression free survival vs docetaxel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results